Lilly Pulitzer is serving up a Valentine's Day partnership with Lele Sadoughi, the New York-based accessories brand. Marking their second collaboration, "Lilly Loves Lele" is a six-piece limited ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

On the topic of manufacturing, Lilly has spent the past few years laying out billions of dollars to grow production capacity for Mounjaro and Zepbound. Despite the formal conclusion of Lilly’s ...

Boris Becker's ex-wife Lilly has won the German version of I'm A Celebrity... Get Me Out Of Here! after stealing the hearts of the nation. The former Wimbledon tennis star, 57, has endured a ...

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

Bell’s career as a cartoonist spans decades, earning him significant accolades, including the 2019 Pulitzer Prize for editorial cartoons. His award-winning work, praised for tackling issues such ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Pulitzer Prize-winning cartoonist Darrin Bell has been arrested on suspicion of possessing child sexual abuse videos, including AI-generated material. The Sacramento County Sheriff's Office said ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...

Shares of Eli Lilly (LLY) and other pharmaceutical companies dropped significantly on Friday. The selloff was triggered by the announcement that the Department of Health and Human Services ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.